ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)